Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Medtronic
Covington
US Army
Chubb

Generated: September 20, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,987,292

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,987,292
Title:Rifaximin anti-rectal dysfunction preparation
Abstract: The present invention relates to compositions and methods for treating rectal disorders.
Inventor(s): Safdi; Alan (Cincinnati, OH), Taylor; David (Chapel Hill, NC)
Assignee: Salix Pharmaceuticals, Ltd. (Raleigh, NC)
Application Number:12/224,774
Patent Claims:1. A pharmaceutical preparation comprising nitroglycerin and rifaximin.

2. The pharmaceutical preparation of claim 1, wherein the nitroglycerin comprises from between about 0.1% to about 10% of the preparation by weight.

3. The pharmaceutical preparation of claim 1, wherein the nitroglycerin comprises from between about 10% to about 50% of the preparation by weight.

4. The pharmaceutical preparation of claim 1, wherein the rifaximin comprises from between about 10% to about 99% of the preparation by weight.

5. The pharmaceutical preparation of claim 1, wherein the rifaximin comprises from between about 25 mg to about 800 mg.

6. The pharmaceutical preparation of claim 1, wherein the rifaximin comprises from between about 100 mg to about 200 mg.

7. The pharmaceutical preparation of claim 1, further comprising at least one additional therapeutic agents.

8. The pharmaceutical preparation of claim 7, wherein the at least one additional therapeutic agents is selected from the group consisting of: anti-inflammatory agents, botox, antibiotics, antiviral compounds, anti-neoplastic compounds, anaesthetics, or anti-fungal agents.

9. A pharmaceutical preparation comprising from between about 100 to about 200 mg rifaximin and from between about 0.1% and about 2% hydrocortisone.

10. The pharmaceutical preparation of claim 9, further comprising from between about 0.01% to about 1% nitroglycerine.

11. The pharmaceutical preparation of claim 1, wherein the preparation comprises an enema, a foam, an ointment, a paste, or a suppository.

12. A method of treating a subject suffering from an anal disorder comprising administering an effective amount of an nitroglycerin and rifaximin proximal or to an affected area of the subject.

13. The method of claim 12, wherein the affected area comprises one or more of the external anus or distal anal canal of the subject.

14. The method of claim 12, wherein the anal disorder selected from one or more of anal fissure, anal ulcer, acute hemorrhoidal disease, Crohn's disease, irritable bowel syndrome, hemorrhoidal disease, irritable bowel syndrome, inflammatory bowel disease, travelers' diarrhea, large intestinal anal disease, chronic pancreatitis, pancreatic insufficiency or post-surgical disease.

15. The method of claim 12, wherein the administering is topical.

16. The method of claim 12, wherein the administering is via a suppository.

17. The method of claim 12, wherein the preparation is applied proximal or to the affected area of the external anus or distal anal canal of the subject.

18. The method of claim 12, wherein the nitroglycerin comprises from between about 0.01% to 10% by weight of the preparation.

19. The method of claim 12, wherein the rifaximin comprises from between about 0.01% to 10% by weight of the preparation.

20. The method of claim 12, wherein the preparation further comprises a carrier.

21. The method of claim 20, wherein the carrier is selected from one or more of white petrolatum, mineral oil, lanolin, distilled water, acetone, and cocoa butter.

22. The method of claim 12, further comprising a corticosteroid.

23. The method of claim 12, further comprising a local anesthetic.

24. The method of claim 12, wherein the composition is formulated as an ointment, a cream, a gel, or a lotion.

25. The method of claim 12, wherein the composition is formulated as a liquid or semisolid.

26. The method of claim 12, wherein the composition is formulated as a suppository.

27. A method of assessing the efficacy of an anal disorder treatment in a subject, monitoring the progress of a subject being treated for an anal disorder, or selecting a subject for treatment of an anal disorder, comprising: determining a pre-treatment level of anal disease; administering a therapeutically effective amount of preparation according to claim 1 to the subject; and determining a post-treatment level of anal disease after an initial period of treatment with the preparation.

28. The method of claim 27, wherein the modulation of the level of anal disease indicates efficacy of the treatment.

29. The method of claim 27, wherein a decrease in anal disease indicates that the treatment is efficacious.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledMarch 06, 2007PCT Application Number:PCT/US2007/005846
PCT Publication Date:September 13, 2007PCT Publication Number:WO2007/103448

Details for Patent 8,987,292

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Try a Free Trial Salix Pharmaceuticals, Ltd. (Raleigh, NC) 2026-03-09 RX search
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 002 1991-12-09   Try a Free Trial Salix Pharmaceuticals, Ltd. (Raleigh, NC) 2026-03-09 RX search
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 003 1991-12-09   Try a Free Trial Salix Pharmaceuticals, Ltd. (Raleigh, NC) 2026-03-09 RX search
Allergan BOTOX COSMETIC onabotulinumtoxina VIAL; SINGLE-USE 103000 004 1991-12-09   Try a Free Trial Salix Pharmaceuticals, Ltd. (Raleigh, NC) 2026-03-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Queensland Health
UBS
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.